Innovative Clinical Solutions, Ltd. v. Clinical Research Center, P.C.

173 F. Supp. 2d 826, 2001 U.S. Dist. LEXIS 19500, 2001 WL 1464273
CourtDistrict Court, C.D. Illinois
DecidedNovember 20, 2001
Docket01-3326
StatusPublished

This text of 173 F. Supp. 2d 826 (Innovative Clinical Solutions, Ltd. v. Clinical Research Center, P.C.) is published on Counsel Stack Legal Research, covering District Court, C.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Innovative Clinical Solutions, Ltd. v. Clinical Research Center, P.C., 173 F. Supp. 2d 826, 2001 U.S. Dist. LEXIS 19500, 2001 WL 1464273 (C.D. Ill. 2001).

Opinion

ORDER

SCOTT, District Judge.

This matter came before the Court on November 14, 2001, for hearing on Plaintiffs Innovative Clinical Solutions, Ltd. and Clinical Studies, Ltd.s’ (collectively ICSL) Motion for Temporary Restraining Order. Plaintiffs appeared by attorney Tracy Litzinger. Defendants Anjuli Na-yak, M.D. and Nicholas Nayak, M.D., appeared personally, and attorney Stephen Thomas appeared for all Defendants. For the reasons set forth below, the Motion is DENIED.'

ICSL is a national site management organization engaged in the business of performing clinical drug trials. Defendants Anjuli Nayak, M.D. and Nicholas Nayak, M.D., own Defendant Clinical Research Center, P.C. (CRC). CRC conducted clinical drug trials in Central Illinois. On January 1, 1999, ICSL bought substantially all of the business assets of CRC. As part of the transaction, CRC and the Na-yaks individually entered into a Clinical Research Management Agreement with ICSL (Agreement). The Agreement referred to CRC as Management, and to the Nayaks as Management’s Shareholders. CRC agreed to be responsible for the day-to-day operations of the acquired business. CRC agreed to act, through its employees or agents, as the Principal Investigator for the drug trials at the acquired business location. The Agreement defined the locations of the acquired business as a site. The Principal Investigator of a clinical drug trial is responsible for the trial under Food and Drug Administration rules. Anjuli Nayak was the Principal Investigator on the drug trials at the site. ICSL agreed to perform the business and accounting functions for'the acquired business, including payroll, record maintenance, collection of receivables and payment of bills.

The Agreement had a term of forty years. If either side defaulted on its performance under the Agreement, the non-breaching party could give notice of default and terminate the Agreement if the default was not cured within thirty days. In addition, either side could terminate the Agreement immediately if the other party filed a voluntary petition in bankruptcy.

The Agreement also had several covenants. The covenant in Section 4 required Management to, “act exclusively on behalf of [ICSL] in managing the Business.... ” Section 7 prohibited either party from disclosing the other party’s confidential information. Section 8 contained restrictive covenants. Section 8.1 stated:

That during the term of this Agreement, and for a period of three (3) years after the termination hereof (the “Restrictive Covenant Period”), Management and Management’s Shareholders shall not, directly or indirectly, for themselves or on behalf of any person or entity (i) *829 contract with another [site management organization] or organization providing site management activities for the purposes of directly or indirectly engaging in the activities contemplated by this Agreement, or (ii) engage in business as a site management organization or provide site management activities....
This provision shall apply individually to each of Management’s Shareholders throughout the Restrictive Covenant Period notwithstanding the fact such Shareholder ceases to be involved with or to be a Shareholder of Management prior to the end of such period.

Section 8.2 provided:

Management and each of Anjuli Nayak and Nicholas Nayak covenant and agree that during the Restrictive Covenant Period, unless otherwise agreed in writing by [IC SL], Management shall not, directly or indirectly, for itself or on behalf of any person or entity, hire or attempt to hire any then current employee of [ICSL] or take any other action which would encourage any such employee to leave the employment of [ICSL]....

Section 8.3 stated:

Notwithstanding anything to the contrary contained in Sections 8.1 or 8.2, in the event that this Agreement ... (ii) is terminated by Management as a result of [ICSL’s] material breach of this Agreement, the Restrictive Covenant Period shall end on the effective date of the termination of the Agreement.

Section 10 of the Agreement authorized filing suit in the event of a breach. The section stated:

Each party expressly recognizes that any breach of this Agreement will result in irreparable injury to the other party and agrees that the other shall be entitled, if it so elects, to institute and prosecute proceedings in any court of competent jurisdiction, either in law or in equity, to obtain damages for any breach of this Agreement, to enforce the specific performance of this Agreement by the other party hereto, and because a remedy at law is inadequate, to enjoin the other party from activities in violation of this Agreement....

Section 14 to the Agreement provided for mediation and arbitration. Section 14.1(a) stated, in part, “If ... a dispute arises between [ICSL] and Management concerning the terms hereof, and such dispute is not resolved within thirty (30) days, the parties agree to attempt to settle the dispute by mediation.... ” Section 14.2 stated in part, “In the event a dispute is not settled through the procedures outlined in Section 14.1, the matter shall be resolved by binding arbitration....

As part of the business acquisition, ICSL also executed a Subordinated Nonnegotiable Note (Note) in the original principal sum of $4,078,269 payable to Anjuli Nayak. The first payment of $2,000,000 was due April 1, 1999. That payment was made. The Note called for a second payment of $1,200,000 on January 1, 2002, and a final payment of $872,000 on January 1, 2004. Filing bankruptcy by ICSL constituted a default under the Note. In the event of default, Anjuli Nayak could accelerate the Note and declare all sums immediately due and payable.

The business acquisition transaction also obligated ICSL to pay a monthly fee to the Nayaks of $75,000. Neither party has submitted a document that memorializes this fee, but both parties agreed at the hearing before this Court that ICSL was obligated to pay such a monthly fee as part of this transaction.

On July 14, 2000, ICSL filed Chapter 11 bankruptcy. ICSL negotiated the bankruptcy reorganization plan with third party *830 creditors before filing. ICSL filed its Plan of Reorganization (Plan) at the time it filed bankruptcy. Defendants claimed that they received no notice of the bankruptcy proceeding, but ICSL claimed that Defendants were notified. ICSL, however, did not submit any evidence regarding the notice given to Defendants.

The Bankruptcy Court entered the Confirmation Order approving the Plan on August 25, 2000. The Confirmation Order stated that non-debtor parties to executory contracts that ICSL assumed under the Plan did not object to the Plan and that all defaults under such contracts would be cured under the Plan. The Agreement constituted an executory contract under the Bankruptcy Code because each party to the Agreement still had substantial obligations to perform at the time of the filing. 11 U.S.C. Section 365; In re Streets & Beard Farm Partnership,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
173 F. Supp. 2d 826, 2001 U.S. Dist. LEXIS 19500, 2001 WL 1464273, Counsel Stack Legal Research, https://law.counselstack.com/opinion/innovative-clinical-solutions-ltd-v-clinical-research-center-pc-ilcd-2001.